Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Silvan Vesenbeckh

Showing results (1-10 of 18) with videos related to

Pageof 2
Sort By:
Lancet (London, England)|April 3, 2012
Elimination of cholera transmissionDidier Bompangue, Guillaume Le Duc, Silvan Vesenbeckh, et al.
BMJ Case Reports|December 13, 2023
SARS-CoV-2 in an immunocompromised host: convalescent plasma therapy and viral evolution elucidated by whole genome sequencingHelena Seth-Smith, Silvan Vesenbeckh, Adrian Egli, et al.
Pneumologie (Stuttgart, Germany)|April 29, 2022
[Cavernous Nontuberculous Mycobacterial Lung Infection in an HIV-positive Patient]Johannes Till Othmer, Nicolas Schoenfeld, Andreas Roth, et al.
Cells, Tissues, Organs|December 28, 2006
Morphometric assessment of the impact of serum thymulin immunoneutralization on pituitary cell populations in peripubertal miceGisela Camihort, Georgina Luna, Silvan Vesenbeckh, et al.
Tuberculosis (Edinburgh, Scotland)|May 10, 2016
Neuroleptic drugs in the treatment of tuberculosis: Minimal inhibitory concentrations of different phenothiazines against Mycobacterium tuberculosisSilvan Vesenbeckh, David Krieger, Gudrun Bettermann, et al.
The European Respiratory Journal|November 13, 2016
Is delamanid a potential agent in the treatment of diseases caused by Mycobacterium avium-intracellulare?David Krieger, Nicolas Schönfeld, Silvan Vesenbeckh, et al.
The European Respiratory Journal|July 25, 2015
Mefloquine as a potential drug against multidrug-resistant tuberculosisDavid Krieger, Silvan Vesenbeckh, Nicolas Schönfeld, et al.
Lung India : Official Organ of Indian Chest Society|December 18, 2012
Minimal inhibitory concentrations of first-line drugs of multidrug-resistant tuberculosis isolatesNicolas Schönfeld, Thorsten Bergmann, Silvan Vesenbeckh, et al.
The European Respiratory Journal|March 24, 2017
Bedaquiline as a potential agent in the treatment of <i>M. intracellulare</i> and <i>M. avium</i> infectionsSilvan Vesenbeckh, Nicolas Schönfeld, David Krieger, et al.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|August 12, 2016
Isoniazid minimal inhibitory concentrations of tuberculosis strains with katG mutationRalf Otto-Knapp, Silvan Vesenbeckh, Nicolas Schönfeld, et al.
Pageof 2

Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
Lancet (London, England)|April 3, 2012
Elimination of cholera transmissionDidier Bompangue, Guillaume Le Duc, Silvan Vesenbeckh, et al.
BMJ Case Reports|December 13, 2023
SARS-CoV-2 in an immunocompromised host: convalescent plasma therapy and viral evolution elucidated by whole genome sequencingHelena Seth-Smith, Silvan Vesenbeckh, Adrian Egli, et al.
Pneumologie (Stuttgart, Germany)|April 29, 2022
[Cavernous Nontuberculous Mycobacterial Lung Infection in an HIV-positive Patient]Johannes Till Othmer, Nicolas Schoenfeld, Andreas Roth, et al.
Cells, Tissues, Organs|December 28, 2006
Morphometric assessment of the impact of serum thymulin immunoneutralization on pituitary cell populations in peripubertal miceGisela Camihort, Georgina Luna, Silvan Vesenbeckh, et al.
Tuberculosis (Edinburgh, Scotland)|May 10, 2016
Neuroleptic drugs in the treatment of tuberculosis: Minimal inhibitory concentrations of different phenothiazines against Mycobacterium tuberculosisSilvan Vesenbeckh, David Krieger, Gudrun Bettermann, et al.
The European Respiratory Journal|November 13, 2016
Is delamanid a potential agent in the treatment of diseases caused by Mycobacterium avium-intracellulare?David Krieger, Nicolas Schönfeld, Silvan Vesenbeckh, et al.
The European Respiratory Journal|July 25, 2015
Mefloquine as a potential drug against multidrug-resistant tuberculosisDavid Krieger, Silvan Vesenbeckh, Nicolas Schönfeld, et al.
Lung India : Official Organ of Indian Chest Society|December 18, 2012
Minimal inhibitory concentrations of first-line drugs of multidrug-resistant tuberculosis isolatesNicolas Schönfeld, Thorsten Bergmann, Silvan Vesenbeckh, et al.
The European Respiratory Journal|March 24, 2017
Bedaquiline as a potential agent in the treatment of <i>M. intracellulare</i> and <i>M. avium</i> infectionsSilvan Vesenbeckh, Nicolas Schönfeld, David Krieger, et al.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|August 12, 2016
Isoniazid minimal inhibitory concentrations of tuberculosis strains with katG mutationRalf Otto-Knapp, Silvan Vesenbeckh, Nicolas Schönfeld, et al.
Pageof 2